Eton Pharmaceuticals (NASDAQ:ETON) Sets New 1-Year High Following Earnings Beat

Eton Pharmaceuticals, Inc. (NASDAQ:ETON)’s share price reached a new 52-week high during trading on Friday following a better than expected earnings announcement. The stock traded as high as $52.85 and last traded at $58.0120, with a volume of 41528 shares trading hands. The stock had previously closed at $40.80.

The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.28. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The business had revenue of $37.59 million during the quarter, compared to analyst estimates of $27.11 million.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Eton reported quarterly EPS of $0.43, compared with the $0.15 consensus estimate, while revenue reached $37.59 million versus expectations of $27.11 million. Zacks cited adjusted EPS of $0.35, up from a loss of $0.10 a year earlier. The results point to improving commercial performance and operating leverage. Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst remains bullish despite estimate reductions. HC Wainwright maintained a “Buy” rating and a $65 price target, above the stock’s recent opening price of $40.80. That target suggests the firm still sees substantial upside from Eton’s rare-disease portfolio and future product growth. HC Wainwright Issues Negative Outlook for ETON Earnings
• Neutral Sentiment: Management discussed the quarterly results and outlook on its earnings call. The call may provide additional detail on product launches, commercial execution and the company’s development pipeline, but the supplied report does not identify a new material announcement or specific guidance change. Eton Pharmaceuticals Q2 2026 Earnings Call Transcript
• Negative Sentiment: HC Wainwright reduced its long-term EPS forecasts. Estimates were cut to $1.28 from $1.83 for FY2027, $2.23 from $3.50 for FY2028, $4.25 from $5.85 for FY2029 and $6.53 from $8.65 for FY2030. Although the Buy rating and $65 target were retained, the revisions signal more cautious expectations for Eton’s future earnings growth. HC Wainwright Earnings Estimates

Analysts Set New Price Targets

A number of brokerages recently issued reports on ETON. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. HC Wainwright boosted their price objective on shares of Eton Pharmaceuticals from $65.00 to $70.00 and gave the stock a “buy” rating in a report on Friday. Craig Hallum upped their price objective on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a research report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. Finally, Canaccord Genuity Group began coverage on Eton Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $60.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $55.75.

Insiders Place Their Bets

In related news, insider David Krempa sold 42,797 shares of the company’s stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83. Following the sale, the insider owned 25,249 shares of the company’s stock, valued at $843,064.11. The trade was a 62.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the transaction, the director directly owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. The trade was a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 150,000 shares of company stock valued at $4,853,921. Corporate insiders own 16.49% of the company’s stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the company. Quarry LP acquired a new stake in shares of Eton Pharmaceuticals during the third quarter worth approximately $37,000. Legal & General Group Plc acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter worth approximately $41,000. Caitong International Asset Management Co. Ltd acquired a new stake in Eton Pharmaceuticals during the 4th quarter valued at $44,000. China Universal Asset Management Co. Ltd. bought a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth $74,000. Finally, Persistent Asset Partners Ltd bought a new stake in Eton Pharmaceuticals during the 2nd quarter worth about $90,000. 27.86% of the stock is owned by institutional investors.

Eton Pharmaceuticals Stock Up 42.0%

The stock has a market cap of $1.59 billion, a price-to-earnings ratio of -815.90 and a beta of 0.86. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. The firm’s 50-day simple moving average is $38.47 and its two-hundred day simple moving average is $28.38.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.